Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States, announced today that it will expand its award-winning line of Select Oil brand products to Pennsylvania — the fifth most populated state in the U.S. Starting today, Select’s best-selling Elite Live cartridges will be available at dispensaries across the state.

Select, America’s #1 Cannabis Oil Brand, was acquired by Curaleaf in February 2020 and can be found in over 1,000 dispensaries in 16 states, including Arizona, California, Colorado, Connecticut, Florida, Illinois, Maine, Massachusetts, Maryland, Michigan, Nevada, New York, Ohio, Oklahoma, Oregon, and Pennsylvania. With plans to expand its product line to New Jersey and Utah by the first quarter of 2021, Select is well on track to become the first nationally recognized cannabis brand. As a recognized industry leader, Select has set the bar for stringent quality standards while continuing to pursue progress and innovation.

Products slated to launch in Pennsylvania include Select Elite Live and Select Elite — the brand’s most popular product — and Select Ratio Drops, which allow for a personalized experience with four varieties, including 1:1, 4:1, 18:1, and THC.

“With the addition of Pennsylvania, an important East Coast market, the Select brand is now available to over 4.1 million registered medical patients across the country, which is a remarkable milestone,” said Joe Bayern, President of Curaleaf. “As an industry leader, we feel it’s both an honor and our responsibility to make the most innovative consumer products with consistent quality accessible to our patients and customers across the U.S.”

In July 2020, Curaleaf closed on its acquisition of Grassroots, allowing the Company to continue developing innovative products serving additional communities across the United States, including Pennsylvania. This news follows last week’s passage of adult use ballot measures in Montana, South Dakota, Arizona, and New Jersey, a clean sweep for cannabis on the ballot box nationwide.

According to the Pennsylvania Department of Health’s Medical Marijuana Two Year Final Report published in May 2020, there are 297,317 registered patients with the state, 29,040 registered caregivers, and 1,349 licensed physicians from the state who may recommend medical cannabis for 23 qualifying medical conditions. For more information about Pennsylvania’s Medical Marijuana Program, visit

Select products will be available at many of Pennsylvania’s leading dispensaries, including the nine Herbology retail locations, which will operate under the Curaleaf brand pending regulatory approval. To find a dispensary near you that carries Select products, go to and click “Find Us” for an interactive map of locations.

About Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is the leading vertically integrated U.S. multi-state cannabis operator with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 95 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 3,000 team members across the United States. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information please visit